期刊
EXPERT REVIEW OF ANTICANCER THERAPY
卷 17, 期 8, 页码 681-685出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14737140.2017.1331736
关键词
Non-small cell lung cancer; next generation sequencing; circulating free DNA; EGFR; ALK; limitations
类别
资金
- Centre Hospitalier Universitaire de Nice
- Centre Antoine Lacassagne
- Institut National du Cancer
- Canceropole PACA
Introduction: The advent of genomic based precision medicine led to the implementation of biomarker testing in metastatic non-small cell lung cancer (NSCLC) patients. Next generation sequencing (NGS) has been recently implemented to routine diagnostic requirements in lung oncology. Areas covered: Two cases of patients with metastatic NSCLC for whom NGS analysis performed on both tumor and liquid biopsy has not improved the clinical course of their disease are reported. These cases illustrate the difficulty of the so-called personalized or precision' medicine in clinical routine practice for metastatic NSCLC. Expert commentary: Discovery and detection of critical cancer-gene alterations better indicates targeted therapies that must be administered to improve the care of NSCLC patients in the personalized medicine era. There has been much interest in the literature and the scientific community for NGS tailored therapies approach for patients. However, there may be a gap between this theoretical stratified medicine and clinical practice. The advantages and drawbacks of NGS on tumor tissue and cell-free DNA for metastatic NSCLC are discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据